TRADE LAW | 2025-12-24

US-UK Pharmaceutical Pricing Agreement December 2025: Section 232 Exemption and NICE QALY Changes Benefit California Importers

December 1, 2025 announcement under US-UK Economic Prosperity Deal delivers Section 232 tariff exemption for UK pharmaceuticals as United Kingdom commits to 25% net price increase, VPAG rebate reduction to 14.5%, and NICE QALY threshold expansion, making UK the only country with zero percent pharmaceutical tariffs while creating strategic advantages for California medical technology and pharmaceutical importers

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

On December 1, 2025, the United States Trade Representative, Department of Commerce, and Department of Health and Human Services jointly announced a comprehensive pharmaceutical pricing agreement with the United Kingdom, establishing the framework for unprecedented tariff exemptions and market acces

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301